Cefditoren Pivoxil HCl | CAS#1448435-17-3 | cephalosporin antibiotic| MedKoo

MedKoo Cat#: 565600 | Name: Cefditoren Pivoxil HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefditoren Pivoxil is a semi-synthetic, broad-spectrum, beta-lactamase resistant, third-generation cephalosporin antibiotic with bactericidal activity. Cefditoren pivoxil is a prodrug that is rapidly hydrolyzed by intestinal esterases during absorption to the microbiologically active cefditoren, an active aminothiazolyl cephalosporin. Cefditoren inactivates penicillin binding proteins (PBPs) thereby interfering with peptidoglycan synthesis and inhibiting bacterial cell wall synthesis.

Chemical Structure

Cefditoren Pivoxil HCl

CAS#1448435-17-3 (pivoxil HCl)

Theoretical Analysis

MedKoo Cat#: 565600

Name: Cefditoren Pivoxil HCl

CAS#: 1448435-17-3 (pivoxil HCl)

Chemical Formula: C25H29ClN6O7S3

Exact Mass: 0.0000

Molecular Weight: 657.17

Elemental Analysis: C, 45.69; H, 4.45; Cl, 5.39; N, 12.79; O, 17.04; S, 14.64

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

117467-28-4 (free base) 442852-27-9 (tosylate) 442852-31-5 (oxalate) 442852-33-7 (sulfate) 1448435-17-3 (pivoxil HCl) 442852-29-1 (mesylate)

Synonym

Cefditoren Pivoxil HCl; Cefditoren Pivoxil hydrochloride ME-1207; ME 1207; ME1207; CDTR-PI; Cefditoren pivoxil; trade name Spectracef; Meiact.

IUPAC/Chemical Name

(Pivaloyloxy)methyl (6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((Z)-2-(4-methylthiazol-5-yl)vinyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate hydrochloride

InChi Key

AFZFFLVORLEPPO-UVYJNCLZSA-N

InChi Code

InChI=1S/C25H28N6O7S3/c1-12-15(41-10-27-12)7-6-13-8-39-21-17(29-19(32)16(30-36-5)14-9-40-24(26)28-14)20(33)31(21)18(13)22(34)37-11-38-23(35)25(2,3)4/h6-7,9-10,17,21H,8,11H2,1-5H3,(H2,26,28)(H,29,32)/b7-6-,30-16-/t17-,21-/m1/s1

SMILES Code

O=C(C(N12)=C(/C=C\C3=C(C)N=CS3)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O)OCOC(C(C)(C)C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 657.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sato E, Kudo S, Takiyama H. Study on Control of pH-Modulation Crystallization Utilizing Concept of Dissociation Equilibrium. Chem Pharm Bull (Tokyo). 2019;67(5):461-466. doi: 10.1248/cpb.c18-01004. PubMed PMID: 31061371. 2: Miyazaki T, Fukushima K, Hashiguchi K, Inoue Y, Mihara T, Sawai T, Suyama N, Kobayashi T, Kondo A, Fukuda Y, Harada Y, Sasaki E, Kaku N, Ide S, Takazono T, Saijo T, Kosai K, Morinaga Y, Nakamura S, Yamamoto K, Imamura Y, Izumikawa K, Yanagihara K, Kohno S, Mukae H. Efficacy and safety of cefditoren pivoxil for exacerbations of chronic obstructive pulmonary disease: A prospective multicenter interventional study. J Infect Chemother. 2019 Apr 11. pii: S1341-321X(19)30082-0. doi: 10.1016/j.jiac.2019.03.018. [Epub ahead of print] PubMed PMID: 30982729. 3: Fernández Ruano ML, Besga García B, Montero Plata A, Dulín Íñiguez E. [False positive on neonatal screening: C5-carnitin increase in newborns due to pre-labour treatment with cefditoren pivoxil]. Rev Esp Salud Publica. 2018 Jun 4;92. pii: e201806025. Spanish. PubMed PMID: 29863107. 4: Ito M, Fukuda M, Suzuki Y, Wakamoto H, Ishii E. Carnitine-related hypoglycemia caused by 3 days of pivalate antibiotic therapy in a patient with severe muscular dystrophy: a case report. BMC Pediatr. 2017 Mar 14;17(1):73. doi: 10.1186/s12887-017-0835-7. PubMed PMID: 28292283; PubMed Central PMCID: PMC5351108. 5: Savlevich EL, Kozlov VS, Zharkykh MA. [A study of the efficacy and safety of new cephalosporin in the treatment of acute bacterial rhinosinusitis]. Vestn Otorinolaringol. 2016;81(6):73-77. doi: 10.17116/otorino201681673-77. Russian. PubMed PMID: 28091482. 6: Sadahira T, Wada K, Araki M, Ishii A, Takamoto A, Kobayashi Y, Watanabe M, Watanabe T, Nasu Y, Kumon H; Okayama Urological Research Group (OURG). Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis: multicentre, randomized, open-label trial. J Antimicrob Chemother. 2017 Feb;72(2):529-534. doi: 10.1093/jac/dkw424. Epub 2016 Oct 12. PubMed PMID: 27733519. 7: Kato H, Sasaki S, Sekiya N. Primary cellulitis and cutaneous abscess caused by Yersinia enterocolitica in an immunocompetent host: A case report and literature review. Medicine (Baltimore). 2016 Jun;95(26):e3988. doi: 10.1097/MD.0000000000003988. Review. PubMed PMID: 27368001; PubMed Central PMCID: PMC4937915. 8: Barbarroja-Escudero J, Sánchez-González MJ, Antolín-Amérigo D, Rodríguez-Rodríguez M, Salinas P, Fernández-Ortiz A, Alvarez-Mon M. Kounis syndrome induced by cefditoren pivoxil. Int J Cardiol. 2016 Mar 15;207:112-4. doi: 10.1016/j.ijcard.2016.01.103. Epub 2016 Jan 11. PubMed PMID: 26800128. 9: Venugopalarao G, Lakshmipathy R, Sarada NC. Preparation and characterization of cefditoren pivoxil-loaded liposomes for controlled in vitro and in vivo drug release. Int J Nanomedicine. 2015 Oct 1;10 Suppl 1:149-57. doi: 10.2147/IJN.S79994. eCollection 2015. PubMed PMID: 26491316; PubMed Central PMCID: PMC4599605. 10: Horkovics-Kovats S, Brunovský P, Pichler A, Bulitta JB. Population data analysis of dissolution time profiles: Assessment of physicochemical properties of the drug, drug particles and the pharmaceutical formulation. Eur J Pharm Sci. 2015 Oct 12;78:245-54. doi: 10.1016/j.ejps.2015.07.017. Epub 2015 Jul 26. PubMed PMID: 26215465. 11: Poachanukoon O, Tangsathapornpong A, Tanuchit S. A Comparison of Cefditoren Pivoxil 8-12 mg/kg/day and Cefditoren Pivoxil 16-20 mg/kg/day in Treatment of Children With Acute Presumed Bacterial Rhinosinusitis: A Prospective, Randomized, Investigator-Blinded, Parallel-Group Study. Clin Exp Otorhinolaryngol. 2015 Jun;8(2):129-35. doi: 10.3342/ceo.2015.8.2.129. Epub 2015 May 13. PubMed PMID: 26045911; PubMed Central PMCID: PMC4451537. 12: Valentín Martín A, Calabuig Muñoz E, Garrido Jareño M, López-Hontangas JL. [Hip prosthesis infection due to Streptococcus gallolyticus subsp. pasteurianus]. Enferm Infecc Microbiol Clin. 2015 Oct;33(8):570-1. doi: 10.1016/j.eimc.2015.02.014. Epub 2015 Mar 29. Spanish. PubMed PMID: 25824992. 13: Gawande VT, Bothara KG, Singh A, Mahajan AA. Identification and Characterization of Hydrolytic Degradation Products of Cefditoren Pivoxil using LC and LC-MS/TOF. Indian J Pharm Sci. 2015 Jan-Feb;77(1):75-82. PubMed PMID: 25767321; PubMed Central PMCID: PMC4355885. 14: Nakajima M, Mizooka M, Tazuma S. Black hairy tongue treated with oral antibiotics: a case report. J Am Geriatr Soc. 2015 Feb;63(2):412-3. doi: 10.1111/jgs.13260. PubMed PMID: 25688627. 15: Onuki T, Kuramochi M, Inagaki M. Mediastinitis of bronchogenic cyst caused by endobronchial ultrasound-guided transbronchial needle aspiration. Respirol Case Rep. 2014 Jun;2(2):73-5. doi: 10.1002/rcr2.53. Epub 2014 Mar 13. PubMed PMID: 25473572; PubMed Central PMCID: PMC4184511. 16: Rivas Castillo FJ, Gómez Martinez JR, López Álvarez F, García Velasco F. Eikenella corrodens: A rare cause of deep neck infection. Acta Otorrinolaringol Esp. 2015 Nov-Dec;66(6):e33-4. doi: 10.1016/j.otorri.2014.04.001. Epub 2014 Oct 11. English, Spanish. PubMed PMID: 25308794. 17: Takahashi Y, Sasabe J, Maeda H, Fujiwara A, Yuda H, Yoshida M, Taguchi O. [First case of lung abscess due to Yersinia pseudotuberculosis in Japan]. Kansenshogaku Zasshi. 2014 Jul;88(4):463-8. Japanese. PubMed PMID: 25199381. 18: Nanishi E, Hoshina T, Ohga S, Nishio H, Hara T. Drug reaction with eosinophilia and systemic symptoms during primary Epstein-Barr virus infection. J Microbiol Immunol Infect. 2015 Feb;48(1):109-12. doi: 10.1016/j.jmii.2014.06.012. Epub 2014 Jul 26. PubMed PMID: 25074626. 19: Alarfaj NA, Aly FA, El-Tohamy MF. Application of silver nanoparticles to the chemiluminescence determination of cefditoren pivoxil using the luminol-ferricyanide system. Luminescence. 2015 Feb;30(1):91-7. doi: 10.1002/bio.2696. Epub 2014 May 22. PubMed PMID: 24850667. 20: Matsumoto K, Sato N, Mitomi N, Shitara Y, Shibasaki S. Population pharmacokinetics of cefditoren pivoxil in non-infected adults. Jpn J Antibiot. 2014 Feb;67(1):49-66. PubMed PMID: 24809208.